Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Company profile
Ticker
CELU, CELUW
Exchange
Website
CEO
Robert Joseph Hariri
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GX Acquisition Corp.
SEC CIK
Corporate docs
IRS number
831702591
CELU stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
15 Mar 24
8-K
Material Modifications to Rights of Security Holders
26 Feb 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Regulation FD Disclosure
12 Feb 24
DEF 14A
Definitive proxy
2 Feb 24
PRE 14A
Preliminary proxy
23 Jan 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Celularity Announces Net Sales and Total Revenue Expectations
9 Jan 24
10-Q
2023 Q3
Quarterly report
2 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.10 mm | 15.10 mm | 15.10 mm | 15.10 mm | 15.10 mm | 15.10 mm |
Cash burn (monthly) | 937.00 k | 3.53 mm | 33.09 mm | 15.56 mm | 2.77 mm | 5.33 mm |
Cash used (since last report) | 5.60 mm | 21.12 mm | 197.88 mm | 93.09 mm | 16.59 mm | 31.86 mm |
Cash remaining | 9.49 mm | -6.03 mm | -182.78 mm | -77.99 mm | -1.49 mm | -16.76 mm |
Runway (months of cash) | 10.1 | -1.7 | -5.5 | -5.0 | -0.5 | -3.1 |
Institutional ownership, Q2 2022
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.70 mm |
Total shares | 517.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Linden Capital | 517.77 k | $5.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Kyle Fletcher | Class A Common Stock | Payment of exercise | Dispose F | No | No | 5.68 | 617 | 3.50 k | 21,105 |
13 Mar 24 | Kok Thay Lim | Warrants Class A Common Stock | Other | Acquire J | Yes | No | 5.895 | 300,000 | 1.77 mm | 300,000 |
17 Feb 24 | John R Haines | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.434 | 70,350 | 30.53 k | 389,497 |
17 Feb 24 | David C Beers | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.434 | 43,968 | 19.08 k | 243,437 |
17 Feb 24 | Stephen Brigido | Class A Common Stock | Payment of exercise | Dispose F | No | No | 0.434 | 32,720 | 14.20 k | 197,406 |
16 Feb 24 | John R Haines | Stock Option Grant Class A Common Stock | Grant | Acquire A | No | No | 0.434 | 216,014 | 93.75 k | 216,014 |
16 Feb 24 | David C Beers | Stock Option Grant Class A Common Stock | Grant | Acquire A | No | No | 0.434 | 183,612 | 79.69 k | 183,612 |
16 Feb 24 | Stephen Brigido | Stock Option Grant Class A Common Stock | Grant | Acquire A | No | No | 0.434 | 183,612 | 79.69 k | 183,612 |
News
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
26 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 Mar 24
Workday, Domino's And 3 Stocks To Watch Heading Into Monday
26 Feb 24
12 Health Care Stocks Moving In Friday's After-Market Session
23 Feb 24
Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated As A Carrier Of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells In The Treatment Of Severe Ocular Surface Disease
14 Feb 24
Press releases
Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm
22 Mar 24
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
20 Mar 24
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
14 Mar 24
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
12 Mar 24
Celularity Announces 1-for-10 Reverse Stock Split
23 Feb 24